

97/937232



The
Patent
Office

PCT/EP 00 / 01444

REC'D 23 APR 2000
WIPROSTOR IN PCT

EPO0/01444

PRIORITY DOCUMENT
SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH
RULE 17.1(a) OR (b)

EPO - DG 1
23. 02. 2000

The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ

(86)


(4)

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.


Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.



Signed *Andrew Gersey*
Dated 21 January 2000

Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)



24MAR99 E434813-1 D10009
F01/7700 0.00 - 9906640.9

The Patent Office

Cardiff Road
Newport
Gwent NP9 1RH

1. Your reference

CGP / PG3654

2. Patent application number

(The Patent Office will fill in this part)

24 MAR 1999

9906640.9

3. Full name, address and postcode of the or of each applicant (underline all surnames)

GLAXO GROUP LTD

GLAXO WELLSOME HOUSE

BERKELEY AVENUE

GREEN FORD

MIDDLESEX UB6 0NN

UNITED KINGDOM

Patents ADP number (if you know it)

If the applicant is a corporate body, give the country/state of its incorporation

473587003

4. Title of the invention

VALVE

5. Name of your agent (if you have one)

DR CHRISTOPHER G PIKE

"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)

PIKE & CO.

3 KLONDYKE

MARLOW

BUCKS

SL7 2QQ

Patents ADP number (if you know it)

7593781001

6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (if you know it) the or each application number

Country

Priority application number
(if you know it)

Date of filing
(day / month / year)

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

Number of earlier application

Date of filing
(day / month / year)

8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer 'Yes' if:

YES

a) any applicant named in part 3 is not an inventor, or

b) there is an inventor who is not named as an applicant, or

c) any named applicant is a corporate body.

See note (d))

Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form 0

Description 8

Claim(s) 3

Abstract 1

Drawing(s) 3

10. If you are also filing any of the following, state how many against each item.

Priority documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (Patents Form 7/77)

Request for preliminary examination and search (Patents Form 9/77)

Request for substantive examination (Patents Form 10/77)

Any other documents (please specify)

11.

I/We request the grant of a patent on the basis of this application.

Signature

Handwritten signature

Date 23 MARCH 99

DR C G PIKE - AGENT FOR THE APPLICANT

12. Name and daytime telephone number of person to contact in the United Kingdom

DR C G PIKE

01628 471869

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.
- Write your answers in capital letters using black ink or you may type them.
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- If you have answered 'Yes' Patents Form 7/77 will need to be filed.
- Once you have filled in the form you must remember to sign and date it.
- For details of the fee and ways to pay please contact the Patent Office.

Valve

5 This invention relates to a valve for an aerosol container with the aid of which a quantity of the contents thereof can be dispensed. The invention has particular application to the dispensing of metered doses of medicaments, though it is applicable to the dispensing of aerosols generally.

10 Containers for aerosol formulations commonly comprise a vial body coupled to a valve. The valve comprises a valve stem through which the formulations is dispensed. Generally the valve includes a rubber valve seal intended to allow reciprocal movement of the valve stem while preventing leakage of propellant from the container.

15 It has been found that in some conventional devices the valve stem tends to stick, pause, or drag during the actuation cycle with the result that the user perceives a 'notchiness' as the valve stem is depressed and released. This may be partly caused by the drug sedimenting or precipitating out of the drug-propellant suspension or solution formulation and depositing on the internal valve components, the presence of drug on the sliding interface creating
20 increased friction during operation.

Prior art seals generally comprise a rubber ring formed by stamping out of a ring shape from a sheet of rubber material. The ring aperture, thus, inevitably has square-cut edges which present a relatively high area of contact between the
25 seal and the stem. Furthermore, when the valve stem is moved in such square-cut seals the seal deforms in such a way that the surface area, and hence the frictional contact area, between the seal and stem increases.

30 The Applicants have now found that the above described problem of notchiness may be ameliorated without comprising sealing performance if the valve seal is shaped such as to reduce the area of contact between the seal and the stem. If a manufacturing process based upon moulding is employed a ring may be formed having a ring aperture with rounded or otherwise shaped edges. When such a rounded or shaped-edge ring is used as a valve seal the area of contact
35 between the seal and the stem is less than that for a ring of equivalent

thickness having square-cut edges. On movement of the stem within the seal there is also less tendency for the seal to deform such as to increase the contact area between the seal and the stem.

5 According to the present invention there is provided a valve for an aerosol container, the valve comprising a valve body; within said valve body, a sealing ring; and receivable by said sealing ring, a valve stem having a dispensing
10 passage, the valve stem being slidably movable within the sealing ring from a valve-closed position to a valve-open position in which the interior of the valve body is in communication with the dispensing passage, wherein the sealing ring is shaped such as to reduce the contact area between the sealing ring and the valve stem.

15 Preferably, the area of contact between the sealing ring and the valve stem is less than 90%, more preferably less than 70%, most preferably less than 50% of what the area of contact would be if the stem-receiving aperture of the sealing ring had square-cut edges.

20 Preferably, the sealing ring is formable by a moulding process.

Preferably, the sealing ring is not movable relative to the valve body, that is to say it is somehow fixed thereto. More preferably, the sealing ring is held within a cavity in the valve body.

25 In one aspect, the stem-receiving part of the sealing ring has rounded edges.

In another aspect, the stem-receiving part of the sealing ring presents a lobed surface to the stem. That is to say the surface comprises one or more lobe features. Preferably, the lobed surface and the stem-receiving part of the stem
30 define one or more wells. More preferably, the one or more wells comprise lubricant material.

35 Preferably, the valve is a metering valve in which the valve body has a metering chamber, a sampling chamber and therebetween is provided a second sealing ring within which the stem is slidably movable, the valve stem having a transfer

passage such that in the valve-closed position the dispensing passage is isolated from the metering chamber and the metering chamber is in communication with the sampling chamber via said transfer passage, and in the valve-open position the dispensing passage is in communication with the metering chamber and the transfer passage is isolated from the metering chamber, wherein the second sealing ring is shaped such as to reduce the contact area between the second sealing ring and the valve stem.

Preferably, the area of contact between the second sealing ring and the valve stem is less than 90%, more preferably less than 70%, most preferably less than 50% of what the area of contact would be if the stem-receiving aperture of the second sealing ring had square-cut edges.

Preferably, the sealing ring and any second sealing ring is formable by a moulding process.

Preferably, the second sealing ring is not movable relative to the valve body. More preferably, the second sealing ring is held within a cavity in the valve body.

In one aspect, the stem-receiving part of the second sealing ring has rounded edges.

In another aspect, the stem-receiving part of the second sealing ring presents a lobed surface to the stem. Preferably, the lobed surface and the stem-receiving part of the stem define one or more wells. More preferably, the one or more wells comprise lubricant material.

Preferably, the stem comprises lubricant material. Suitably, the valve stem comprises up to 30%, preferably from 5 to 20% lubricant material.

Preferably, the sealing ring and/or second sealing ring comprises lubricant material. Suitably, the sealing ring and/or second sealing ring comprises up to 30%, preferably from 5 to 20% lubricant material.

The term 'lubricant' herein means any material which reduces friction between the valve stem and seal. Suitable lubricants include silicone oil or a fluorocarbon polymer such as polytetrafluoroethane (PTFE).

- 5 Lubricant can be applied to the stem, sealing ring or second sealing ring by any suitable process including coating and impregnation, such as by injection or a tamponage process.

10 According to another aspect of the present invention, there is provided an aerosol container comprising a valve as described hereinabove.

Preferably, the aerosol container comprises a suspension of a medicament in a propellant.

15 Preferably, the propellant is liquefied HFA134a or HFA-227.

Preferably, the medicament is selected from albuterol, salmeterol, fluticasone propionate and beclomethasone dipropionate and salts or solvates thereof and any combination thereof.

20 The invention will now be described further with reference to the accompanying drawing in which:

Figure 1 is a section through a metering valve according to the invention;

25 Figure 2 is a close-up sectional view of a seal-stem contact point in a valve according to the invention;

30 Figure 3 is a close-up sectional view of a seal-stem contact point in a valve according to the invention;

Figure 4a is a close-up sectional view of a seal-stem contact point in a prior art valve in a rest position; and

Figure 4b is a close-up sectional view of a seal-stem contact point in the valve of Figure 4a in an active position.

5 A valve according to the invention is shown in Figure 1 and comprises a valve body 1 sealed in a ferrule 2 by means of crimping, the ferrule itself being set on the neck of a container (not shown) with interposition of a gasket 3 in a well-known manner. The container is loadable with a suspension of medicament, such as salmeterol xinafoate in liquid propellant HFA134a.

10 The valve body 1 is formed at its lower part with a metering chamber 4, and its upper part with a sampling chamber 5 which also acts as a housing for a return spring 6. The words "upper" and "lower" are used for the container when it is in a use orientation with the neck of the container and valve at the lower end of the container which corresponds to the orientation of the valve as shown in Figure
15 1. Inside the valve body 1 is disposed a valve stem 7, a part 8 of which extends outside the valve through lower stem seal 9 and ferrule 2. The stem part 8 is formed with an inner axial or longitudinal canal 10 opening at the outer end of the stem and in communication with a radial passage 11.

20 The upper portion of stem 7 has a diameter such that it can pass slidably through an opening in an upper stem seal 12 and will engage the periphery of that opening sufficiently to provide a seal. The stem seals 9 and 12 are made by a moulding process and have rounded points of contact with the valve stem 7. Upper stem seal 12 is held in position against a step 13 formed in the valve
25 body 1 between the said lower and upper parts by a sleeve 14 which defines the metering chamber 4 between lower stem seal 9 and upper stem seal 12. The valve stem 7 has a passage 15 which, when the stem is in the inoperative position shown, provides a communication between the metering chamber 4 and sampling chamber 5, which itself communicates with the interior of the container
30 via orifice 16 formed in the side of the valve body 1.

Valve stem 7 is biased downwardly to the inoperative position by return spring 6 and is provided with a shoulder 17 which abuts against lower stem seal 9. In the inoperative position as shown in Figure 1 shoulder 17 abuts against lower
35 stem seal 9 and radial passage 11 opens below lower stem seal 9 so that the

metering chamber 4 is isolated from canal 10 and suspension inside cannot escape.

5 A ring 18 having a "U" shaped cross section extending in a radial direction is disposed around the valve body below orifice 16 so as to form a trough 19 around the valve body. As seen in Figure 1 the ring is formed as a separate component having an inner annular contacting rim of a diameter suitable to provide a friction fit over the upper part of valve body 1, the ring seating against step 13 below the orifice 16. However, the ring 18 may alternatively be formed
10 as an integrally moulded part of valve body 1.

To use the device the container is first shaken to homogenise the suspension within the container. The user then depresses the valve stem 7 against the force of the spring 6. When the valve stem is depressed both ends of the passage 15
15 come to lie on the side of upper stem seal 12 remote from the metering chamber 4. Thus a dose is metered within the metering chamber. Continued depression of the valve stem will move the radial passage 11 into the metering chamber 4 while the upper stem seal 12 seals against the valve stem body. Thus, the metered dose can exit through the radial passage 11 and the outlet canal 10.

20 Releasing the valve stem causes it to return to the illustrated position under the force of the spring 6. The passage 15 then once again provides communication between the metering chamber 4 and sampling chamber 5. Accordingly, at this stage liquid passes under pressure from the container through orifice 16,
25 through the passage 15 and thence into the metering chamber 4 to fill it.

Figure 2 shows a cut-away detail of a seal-stem contact point of a valve herein. The upright valve stem 108 which has a circular cross-section is sealingly contacted by a sealing ring 112. The ring aperture 130 of the sealing ring 112
30 has rounded edges. It may be understood that the area of contact of the ring 112 with the stem 108 is less than it would be if the ring 112 had square-cut edges. When the stem 108 is moved upwards, the ring 112 will tend to flex into free-space 140.

Figure 3 shows a cut-away detail of a seal-stem contact point of a second valve herein. The upright valve stem 208 which has a circular cross-section is sealingly contacted by a sealing ring 212. The ring aperture of the sealing ring 212 is edged by two rounded lobes 230, 232. The area of contact of the ring 212 with the stem 208 is less than it would be if the ring 212 had square-cut edges. When the stem 208 is moved within the ring 212, the ring 212 will tend to flex into free-space 240 and well 242. The well 242 may be wholly or partially filled with a lubricant material.

Figures 4a and 4b. show a cut-away detail of a seal-stem contact point of a prior art valve, wherein Figure 4a shows a rest configuration and Figure 4b shows the configuration when the valve is in an active position. The upright valve stem 308 which has a circular cross-section is sealingly contacted by a sealing ring 312. The ring aperture 330 of the sealing ring 312 has square-cut edges 330. When the stem is moved upwards as shown in Figure 4b, the ring 312 is deformed and spreads out such that the area of contact between the ring 312 and the stem 308 is increased. The frictional contact between the ring 312 and stem is thus, also increased.

The aerosol container and valve of the invention is suitable for dispensing medicament, particularly for the treatment of respiratory disorders. Appropriate medicaments may thus be selected from, for example, analgesics, e.g., codeine, dihydromorphine, ergotamine, fentanyl or morphine; anginal preparations, e.g., diltiazem; antiallergics, e.g., cromoglycate, ketotifen or nedocromil; anti-infectives e.g., cephalosporins, penicillins, streptomycin, sulphonamides, tetracyclines and pentamidine; antihistamines, e.g., methapyrilene; anti-inflammatories, e.g., beclomethasone dipropionate, fluticasone propionate, flunisolide, budesonide, rofleponide, mometasone furoate or triamcinolone acetonide; antitussives, e.g., noscapine; bronchodilators, e.g., albuterol, salmeterol, ephedrine, adrenaline, fenoterol, formoterol, isoprenaline, metaproterenol, phenylephrine, phenylpropanolamine, pirbuterol, reproterol, rimiterol, terbutaline, isoetharine, tulobuterol, or (-)-4-amino-3,5-dichloro- α -[[[6-[2-(2-pyridinyl)ethoxy] hexyl]methyl] benzenemethanol; diuretics, e.g., amiloride; anticholinergics, e.g., ipratropium, tiotropium, atropine or oxitropium; hormones, e.g., cortisone, hydrocortisone or prednisolone; xanthines, e.g., aminophylline,

choline theophyllinate, lysine theophyllinate or theophylline; therapeutic proteins and peptides, e.g., insulin or glucagon. It will be clear to a person skilled in the art that, where appropriate, the medicaments may be used in the form of salts, (e.g., as alkali metal or amine salts or as acid addition salts) or as esters (e.g., lower alkyl esters) or as solvates (e.g., hydrates) to optimise the activity and/or stability of the medicament.

Preferred medicaments are selected from albuterol, salmeterol, fluticasone propionate and beclomethasone dipropionate and salts or solvates thereof, e.g., the sulphate of albuterol and the xinafoate of salmeterol.

Medicaments can also be delivered in combinations. Preferred formulations containing combinations of active ingredients contain salbutamol (e.g., as the free base or the sulphate salt) or salmeterol (e.g., as the xinafoate salt) in combination with an antiinflammatory steroid such as a beclomethasone ester (e.g., the dipropionate) or a fluticasone ester (e.g., the propionate).

It will be understood that the present disclosure is for the purpose of illustration only and the invention extends to modifications, variations and improvements thereto.

The application of which this description and claims form part may be used as a basis for priority in respect of any subsequent application. The claims of such subsequent application may be directed to any feature or combination of features described therein. They may take the form of product, method or use claims and may include, by way of example and without limitation, one or more of the following claims:

Claims

1. Valve for an aerosol container, the valve comprising a valve body;
within said valve body, a sealing ring; and receivable by said sealing ring, a
5 valve stem having a dispensing passage, the valve stem being slidably movable
within the sealing ring from a valve-closed position to a valve-open position in
which the interior of the valve body is in communication with the dispensing
passage, wherein the sealing ring is shaped such as to reduce the contact area
between the sealing ring and the valve stem.
10
2. Valve according to claim 1, wherein the area of contact between the
sealing ring and the valve stem is less than 90% of what the area of contact
would be if the sealing ring had square-cut edges.
- 15 3. Valve according to either of claims 1 or 2, wherein the sealing ring is
formable by a moulding process.
4. Valve according to any of claims 1 to 3, wherein the sealing ring is not
movable relative to the valve body.
20
5. Valve according to claim 4, wherein the sealing ring is held within a
cavity in the valve body.
6. Valve according to any of claims 1 to 5, wherein the stem-receiving
25 part of the sealing ring has rounded edges.
7. Valve according to any of claims 1 to 5, wherein the stem-receiving
part of the sealing ring presents a lobed surface to the stem.
- 30 8. Valve according to claim 7, wherein the lobed surface and the stem-
receiving part of the stem define one or more wells.
9. Valve according to claim 8, wherein said one or more wells comprise
lubricant material.

10. Valve according to any of claims 1 to 9, wherein the valve body has a metering chamber, a sampling chamber and therebetween is provided a second sealing ring within which the stem is slidably movable, the valve stem having a transfer passage such that in the valve-closed position the dispensing passage is isolated from the metering chamber and the metering chamber is in communication with the sampling chamber via said transfer passage, and in the valve-open position the dispensing passage is in communication with the metering chamber and the transfer passage is isolated from the metering chamber, wherein the second sealing ring is shaped such as to reduce the contact area between the second sealing ring and the valve stem.
11. Valve according to claim 10, wherein the area of contact between the second sealing ring and the valve stem is less than 90% of what the area of contact would be if the second sealing ring had square-cut edges.
12. Valve according to either of claims 10 or 11, wherein the second sealing ring is formable by a moulding process.
13. Valve according to any of claims 10 to 12, wherein the second sealing ring is not movable relative to the valve body.
14. Valve according to claim 13, wherein the second sealing ring is held within a cavity in the valve body.
15. Valve according to any of claims 10 to 14, wherein the stem-receiving part of the second sealing ring has rounded edges.
16. Valve according to any of claims 10 to 15, wherein the stem-receiving part of the second sealing ring presents a lobed surface to the stem.
17. Valve according to claim 16, wherein the lobed surface and the stem-receiving part of the stem define one or more wells.
18. Valve according to claim 17, wherein said one or more wells comprise lubricant material.

19. Valve according to any of claims 1 to 18, wherein the stem comprises lubricant material.
- 5 20. Valve according to any of claims 1 to 19, wherein the sealing ring comprises lubricant material.
21. Valve according to any of claims 10 to 20, wherein the second sealing ring comprises lubricant material.
- 10 22. Aerosol container comprising a valve according to any of claims 1 to 21.
23. Aerosol container according to claim 20 comprising a suspension of a medicament in a propellant.
- 15 24. Aerosol container according to claim 21, wherein, the propellant is liquefied HFA134a or HFA-227.
- 20 25. Aerosol container according to either of claims 21 or 22, wherein the medicament is selected from the group consisting of albuterol, salmeterol, fluticasone propionate, beclomethasone dipropionate, salts or solvates thereof and any combination thereof.

**Abstract**

There is provided a valve for an aerosol container. The valve comprises a valve body; within said valve body, a sealing ring; and receivable by said sealing ring, a valve stem having a dispensing passage. The valve stem is slidably movable within the sealing ring from a valve-closed position to a valve-open position in which the interior of the valve body is in communication with the dispensing passage. The sealing ring is shaped such as to reduce the contact area between the sealing ring and the valve stem. Preferably, the valve is a metering valve.




FIG. 1.

2/3




Fig. 2




Fig. 3

